Clinical trial experience with CA4P anticancer therapy: focus on efficacy, cardiovascular adverse events, and hypertension management.

Gynecol Oncol Res Pract · 2018 · PMC5756341 · PMID 29318022

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Interestingly, post hoc analyses showed a trend toward longer survival with CA4P–CP–bevacizumab compared with CP–bevacizumab in patients with tumors >10 cm (median OS 14.2 vs 11.0 months; HR = 0.67 [95% CI, 0.26–1.70]).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.